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ABSTRACT 
Living organisms contain many bio-molecules that are comprised of oxygen and nitrogen donor atoms and therefore have high 
affinity for metal ions, such as iron, present in the body. The stability constants of these chelates are very high in general. One of 
such molecules is (-)-3-(3,4-dihydroxyphenyl)-L-alanine which is present in brain to control the normal function of neurons. In 
case of neurodisorder disease, Parkinson’s, this molecule is orally administered in the form of tablets. The pH of stomach is acidic 
and blood is about neutral, therefore in the present work, the chelation, stoichiometry and stability of iron complexes of (-)-3-(3,4-
dihydroxyphenyl)-L-alanine is studied at acidic to neutral pH. Reaction of this molecule in vitro showed interesting results. 
Stoichiometry of the complex is found 1:3 and it remains pH independent (in buffered & non buffered solutions).While stability of 
the complex increases with the rise of pH as revealed by molar extinction coefficient values. 
 
Keywords: Iron, Levodopa, stoichiometry, pH effect, molar extinction coefficient. 
1. INTRODUCTION 
Metals by themselves and in proper balance to one another have important biochemical and nutritional functions
1-2. 
The bioavailability of these minerals is also a very important factor, depending on the food source and also upon the 
pH of stomach
3-4. 
Iron plays significant role for normal brain and nerve function through its involvement in the synthesis of 
neurotransmitters
5.  Severe  iron  deficiency  anemia  may  result  in  many  diseases
6.On  the  other  hand  dopamine  is 
considered basic factor, responsible of behavioral changes in neurodisorder disease
7-9. Iron and dopamine both play 
significant role in normal function of brain. Also the excess iron is found in brain in Parkinsonian patients but still the 
relation of iron and dopamine is ambiguous
10-11.  
Dopa  of  dihydroxyphenyl  alanine  is  a  precursor  of  dopamine  and  norepinephrine.  It  is  levorotatory 
stereoisomer of dopa
12 while d-enantiomer leads to clinical side effects
13. Levodopa is (-)-3-(3,4-dihydroxyphenyl)-L-
alanine, (Fig. 1) is a derivative of Amino acid (alanine) containing catechol moiety. Catechol has high affinity for 
metal ions specifically iron, therefore Levodopa is expected to chelate iron strongly
14-17. 
 
Fig-1: (-)-3-(3,4-dihydroxyphenyl)-L-alanine Commonly known as Levodopa 
 
In the beginning part of the project, the complex formation of (-)-3-(3,4-dihydroxyphenyl)-L-alanine with iron was 
carried. Fe
2+ forms intense color complex with (-)-3-(3,4-dihydroxyphenyl)-L-alanine having absorbance maxima in 
visible region. Spectral characteristics of the said complex, stoichiometry and effect of pH on complex formation are 
explored. Current research is carried to investigate the stability of complex at low pH, which in turn is helpful to 
understand the chelation of iron with administered Levodopa in stomach. 
 
2. EXPERIMENTAL 
A. R. grade reagents were used for all the reactions. CO2 free distilled deionized water was used to prepare the 
solution. 
 
2.1 Absorbance maxima: 
To  explore  wavelength  of  the  maximum  absorbance  the  complex  of  Fe
2+  (-)-3-(3,4-dihydroxyphenyl)-L-alanine, 
0.005mmol of Fe
2+ salt solution was mixed with enough excess of levodopa solution (prepared in deionized distilled 
water).  The  stock  solution  was  subjected  to  scanning  in  UV-visible  region  on  GENESYS  6  (Thermo  Electron 
Corporation). Using the resultant spectra, suitable wavelengths were selected for further study. The complex solution 
showed  absorbance  maxima  at  two  wavelengths;  430nm  and  730nm.  The  metal  and  ligand  solutions  have  no 
absorbance at these wavelengths (Fig. 2). All further work was carried out on both wavelengths. 
2.2 Molar extinction coefficients:  
Different dilutions of the stock complex solution were then prepared in deionized distilled water. Absorbance of all 
diluted solutions was recorded at selected wavelengths (430 and 730nm).   was determined as the slope of straight line Pakistan Journal of Chemistry 2013 
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on a graph plotted between recorded absorbance against metal concentration. The same work was repeated using 
buffer of pH 3.0, 4.0, 5.0 and 6.0. 
 
2.3 Mole ratio 
Accurate amount of Ferrous ammonium sulfate was taken to prepare metal solution in deionized distilled water, while 
the ligand solutions were prepared in buffer solutions of desired pH. At each pH, different aliquots of ligand solution 
were added in 0.005mmol metal solution and volume was kept constant for all. The absorbance was recorded at 
430nm and 730nm, while temperature was maintained at 25±1°C. 
 
3. RESULTS AND DISCUSSION 
 
3.1 Spectral Characteristics 
A green colored complex of Fe(II) and levodopa was formed  at pH 4.0, 5.0 and 6.0 at 25+1°C except pH 3.0. 
Absorbances were recorded at both the selected wavelengths. Spectra in Fig. 3 show drastic change with varying pH 
(Fig. 3). No green color was observed in buffer of pH 3.0. Spectra in the above mentioned range has no peak. 
  
 
Fig-2: Spectra of Fe (II) complexed with Levodopa in non-buffered aqueous solution. Fe(II) = 0.05mmol, 10 fold ligand solution 
 
 
Fig-3: Spectra of Fe (II) complexed with Levodopa, pH 4.0, 5.0 and 6.0 buffer solutions. Fe (II) = 0.005 mmol, 10 fold ligand 
solution 
 
3.2 Molar Absorptivity 
Fe(II) and levodopa formed a complex at pH buffer 4.0, 5.0 and 6.0 at 25+1°C and absorbance was recorded at all the 
selected wavelengths and molar absorptivities were evaluated (Figure 4-5,Table-1). Two peaks at 430 and 730nm 
were found 
selected wavelengths increases simultaneously with pH. However in pH 6.0 buffered solutions, peak shift is observedFatima et al, 2013 
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-1cm-1. 
 
 
Table-1: Molar Absorptivity of Fe(II)-Levodopa Complex at different pH at all Selected wavelengths 
pH 
Molar Absobtivity (M
-1cm
-1) 
430nm.  730nm.  615nm. 
Non buffered  237  302.6  ---- 
4.0  783.1  633.7  ---- 
5.0  866.8  796.2  ---- 
6.0  1834  1735  2528 
 
 
 
Fig-4: Molar Absorptivity of Fe (II)-Levodopa Complex, pH 4.0, 5.0 & 6.0, λ = 430nm. 
 
 
 
Fig-5: Molar Absorptivity of Fe (II)-Levodopa Complex, pH 4.0, 5.0 & 6.0, λ = 730nm. 
 
3.3 Stoichiometry 
Applying mole ratio method, In each set, different aliquots of ligand solution were added to 0.005mmol Fe (II) 
solution in order to get 0.5-10 times L:M mole ratio. Gradual increase was observed in absorbance with the increase of 
ligand  to  metal  mole  ratio  (Fig  6).  At  high  concentration  of  ligand  the  absorbance  is  independent  of  Ligand 
concentration. Tangent drawn on the curve in Figure 6-9 gives a value of ~3 showing a 1:3 metal to ligand ratio in the 
complex. 
[Fe(H2O)6]
2+     + H2LD       [Fe(H2O)4LD]+2H3O
+ 
[Fe(H2O)4LD] +H2LD      [Fe(H2O)2(LD)2]
2 +2H3O
+ 
[Fe(H2O)2(LD)2] +H2LD    [Fe(LD)3]   +2H3O
+ 
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Stoichiometry of Fe (II) and Levodopa Complex was further studied on pH 3.0, 4.0, 5.0 and 6.0. Consistency was 
found in the results as shown in the Figure 7-9 (Table-2). At all the considered pH ML3 complex is formed regardless 
of the solution pH. 
 
Table-2: pH effect on the Stoichiometry of Complex 
pH  Stoichiometry Fe
2+(LD)3 
Aqueous (non buffered)  1:3 
4.0  1:3 
5.0  1:3 
6.0  1:3 
 
 
 
Fig-6: Stoichiometry of Fe (II)-Levodopa Complex in non-buffered aqueous solution. Fe (II) = 0.005mmol, λ = 730nm. 
 
 
 
 
Fig-7: Stoichiometry of Fe (II)-Levodopa Complex, pH 4.0, 5.0 and 6.0.  Fe (II) = 0.005mmol, λ = 430nm.
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Fig-8: Stoichiometry of Fe (II)-Levodopa Complex, pH 4.0, 5.0 and 6.0. Fe (II) = 0.005mmol, λ = 615nm. 
 
 
Fig-9: Stoichiometry of Fe (II)-Levodopa Complex, pH 4.0, 5.0 and 6.0. Fe (II) = 0.005 mmol. λ = 730nm. 
 
4. CONCLUSIONS 
Complex formation of Fe (II) L-dopa is studied at pH 3.0, 4.0, 5.0 and 6.0 buffered and also in non buffered media. 
Two distinct peaks were found in complex spectra, one at 430nmand another at 730nm. In pH 6.0 buffer, the 730nm 
peak sharpens while shifted to 615nm. 
At the selected wavelengths, Fe (II):H2L mole ratio plot showed an ML3 complex formation in spite of pH; 
evident of stability of the investigated complex. The same result is verified by molar extinction coefficient values that 
increase with the increase of pH. In ML3 complex, three levodopa molecules occupied all six positions around the 
metal in an octahedral molecule. Thus levodopa acts as bidentate ligand forming a strong chelate.  
Levo-dopa forms very strong complex with Fe(II) at stomach pH. The result is consistent with literature. It 
showed that the Levodopa in drug molecule is chelated by iron and therefore may not efficiently reach to its required 
destination. 
The question arises whether this chelation helps the L-dopa to cross blood brain barrier or not. This important 
point requires further investigation to be explored.  
Since pH of brain is approximately 10. Work at high pH may provide imperative information about chelation 
of Fe(II) by this molecule in brain. In-vitro study at high pH is in progress and will soon be published. 
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